Dual Drug Combo Radiosensitizes ATM-Mutant Prostate Cancer
New study reveals combination therapy targeting ATR and DNA-PKcs kinases dramatically improves radiation response in ATM-deficient prostate cancers.
Summary
Researchers discovered that prostate cancers with ATM mutations maintain DNA repair through backup pathways involving ATR and DNA-PKcs kinases. While PARP inhibitors show limited benefit in these patients, dual inhibition of ATR and DNA-PKcs dramatically enhanced radiation sensitivity. The team tested a novel compound called Compound B that degrades both target kinases simultaneously, showing promise both in lab studies and animal models. This approach could offer new treatment options for the 7.3% of advanced prostate cancer patients with ATM mutations who currently have limited therapeutic choices.
Detailed Summary
ATM mutations occur in 7.3% of advanced castration-resistant prostate cancers, but these patients show limited response to approved PARP inhibitors like Olaparib. Researchers at UT Southwestern generated matched ATM-proficient and ATM-deficient prostate cancer cell lines to understand why these tumors resist treatment.
Using unbiased phosphoproteomic screening after radiation exposure, they discovered that ATM-deficient cells maintain DNA damage response through compensatory activation of ATR and DNA-PKcs kinases. While individual inhibition of either kinase had minimal effect, dual inhibition dramatically radiosensitized ATM-deficient cells and reduced γH2AX DNA damage foci formation by over 50% compared to single treatments.
The combination therapy completely abrogated downstream ATM pathway signaling, including phosphorylation of KAP1 and CHK2 proteins, and impaired replication fork dynamics. To avoid potential toxicity from combining two kinase inhibitors, researchers tested Compound B, a RUVBL1/2 ATPase inhibitor that degrades both ATR and DNA-PKcs proteins simultaneously.
Compound B effectively radiosensitized ATM-deficient cells both in vitro and in mouse xenograft models, mimicking the effects of dual kinase inhibition while using a single agent. The compound reduced replication fork speed and length, indicating disrupted DNA replication processes essential for cancer cell survival.
These findings suggest Compound B combined with radiation could provide a new therapeutic strategy for ATM-mutant prostate cancer patients who currently have limited treatment options beyond standard chemotherapy.
Key Findings
- ATM mutations in prostate cancer are predominantly loss-of-function (69.4% cause protein truncation)
- ATM-deficient cells showed only weak sensitization to PARP inhibitor Olaparib compared to BRCA2-mutant controls
- Dual ATR/DNA-PKcs inhibition reduced γH2AX foci formation by >50% vs single treatments in ATM-deficient cells
- Combination therapy completely eliminated downstream KAP1 and CHK2 phosphorylation in ATM-deficient cells
- Compound B significantly reduced replication fork speed and length compared to vehicle controls
- Dual inhibition markedly radiosensitized ATM-deficient cells in clonogenic survival assays
- Phosphoproteomic analysis identified 8,626 unique phosphopeptides in response to radiation
Methodology
Researchers used CRISPR-Cas9 to generate matched ATM-proficient and ATM-deficient C4-2 and 22Rv1 prostate cancer cell lines. Phosphoproteomic screening analyzed over 8,000 phosphopeptides after 10 Gy radiation exposure. Clonogenic survival assays tested radiation sensitivity with escalating doses. DNA fiber assays measured replication fork dynamics using sequential thymidine analog labeling. Statistical analysis included kinase-substrate enrichment analysis (KSEA) and volcano plot comparisons.
Study Limitations
The study was conducted primarily in cell line models with validation in mouse xenografts, requiring clinical trials to confirm human efficacy and safety. Potential toxicity from dual kinase inhibition remains a concern, though Compound B may mitigate this issue. The research focused specifically on radiation combination therapy, and effects with other DNA-damaging agents remain to be determined.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.